Alluvi, previously BI 4744, offers a significant advance in obesity therapy. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates impressive results in patient https://alluvi-peptides332135.bloggers-hub.com/profile